Association of aspirin use and hormone receptor status with breast cancer risk [1] (multiple letters)

JAMA

Volumn 292, Issue 12, 2004, Pages 1426-1427

  Moorman, Patricia G ^a   Woloshin, Steven ^b   Schwartz, Lisa M ^b   Terry, Mary Beth ^c   Gammon, Marilie ^d   Neugut, Alfred I ^e  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b VA MEDICAL CENTER   (United States)

^c Columbia University ^*  (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ETODOLAC; HORMONE RECEPTOR; IBUPROFEN; KETOPROFEN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; SULINDAC; ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ARTHRITIS; BREAST CANCER; CANCER RISK; CASE CONTROL STUDY; CHEMOPROPHYLAXIS; CHRONIC PAIN; CONFIDENCE INTERVAL; DRUG EFFECT; DRUG USE; HUMAN; LETTER; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; SIDE EFFECT; BREAST TUMOR; NOTE; RISK;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICARCINOGENIC AGENTS; ASPIRIN; BREAST NEOPLASMS; HUMANS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RISK;

EID: 4544260585     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.292.12.1426-b     Document Type: Letter

References (0)